Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington's disease

Elizabeth H. Aylward

Research output: Contribution to journalArticlepeer-review

Abstract

An abundance of research shows that magnetic resonance imaging (MRI) striatal volumes decrease long before diagnosis of Huntington's disease (HD) and closely track disease progression. Additional research indicates that these volumetric measures meet important criteria for a biomarker that can be used in clinical trials: They are 1) objectively measureable; 2) able to predict known endpoints; and 3) associated with known mechanisms of pathology of the disease. Researchers should consider formal application to regulatory agencies for biomarker status of volumetric MRI striatal measures, because these measures are anticipated to contribute significantly in the assessment of treatment effectiveness in HD.

Original languageEnglish (US)
Pages (from-to)1429-1433
Number of pages5
JournalMovement Disorders
Volume29
Issue number11
DOIs
StatePublished - Sep 15 2014

Keywords

  • Biomarker
  • Huntington's disease
  • MRI
  • Striatal volume

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington's disease'. Together they form a unique fingerprint.

Cite this